ArriVent BioPharma Collaborates with Alphamab to Develop Antibody Drug Conjugates for Treating Cancers
Shots:
- ArriVent and Jiangsu Alphamab Biopharmaceuticals have signed a collaboration agreement for the discovery, development & commercialization of new ADCs for cancer treatment
- As per the agreement, the companies will identify ADCs using Alphamab’s linker-payload platform and glycan-conjugation technology. ArriVent gains exclusive worldwide (excl. greater China) rights for its development & commercialization while Alphamab keeps the rights across greater China (outside of mainland China, Hong Kong, Macau & Taiwan)
- Furthermore, Alphamab will receive a total of up to $615.5M incl. upfront as well as regulatory, development & sales milestones for the programs plus tiered sales-based royalties for every ADC
Ref: ArriVent | Image: ArriVent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
